{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:44:42Z","timestamp":1790675082271,"version":"4.1.0"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Patients with cancer cachexia display a general resistance to immune checkpoint inhibitor (ICI) therapy, and baseline ICI catabolic clearance is a predictive indicator for overall survival, independent of dose and drug exposure. Fc-gamma (Fc\u03b3Rs) and neonatal Fc receptors (FcRn) play key roles in ICI clearance and efficacy, and we aimed to determine the impact of cachexia, independent of tumor, on immune cell populations and their Fc receptor (FcR) expression in patients and in murine models of cancer, cachexia, and cancer cachexia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Experimental design<\/jats:title>\n                    <jats:p>Immune cell populations and their FcR expression were measured in tumor-bearing and tumor-free mice, with\/without cachexia, and from patients with non-small cell lung cancer (NSCLC) and renal cell carcinoma. These measures, upon splenocytes and peripheral blood mononuclear cells (PBMCs) in mice and humans respectively, were compared with baseline ICI drug clearance and cachexia phenotype.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Leukocyte populations and Fc\u03b3R in mouse splenocytes displayed distinct expressional patterns when comparing across tumor and cachexia status. Univariate analyses revealed several correlations between Fc\u03b3R expression on patient PBMCs and both ICI clearance and cachexia phenotype. Notably, FcRn expression was unchanged or slightly elevated in tumor-bearing mice and did not correlate with ICI clearance in murine splenocytes or patient leukocytes. Furthermore, immune cell populations and FcR expression were different among tumor types but did not differ in splenocytes of tumor-free mice with Activin A\/IL-6 induced cachexia when compared with vector controls.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings provide the first evidence that FcRs, critical for the efficacy and pharmacokinetics of many ICI and other IgG mAbs, are altered in a tumor-dependent manner. Furthermore, in the absence of a tumor, cachexia phenotype may not coincide with inflammation in the form of altered immune cell populations and elevated catabolic clearance of IgG mAbs, suggesting these features arise from properties intrinsic to the tumor.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1669979","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T06:45:31Z","timestamp":1765953931000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Tumor intrinsic properties dictate Fc receptor expression and cancer cachexia associated increase in checkpoint inhibitor clearance"],"prefix":"10.3389","volume":"16","author":[{"given":"Bryan C.","family":"Remaily","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Lathrop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyeongmin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trang T.","family":"Vu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeoluwa","family":"Adeluola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Stanton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian","family":"Mulcahy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiliang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Granchie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizhen","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Hai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Wedig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Millennium","family":"Manna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaokui","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeovanna","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill A.","family":"Rafael-Fortney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmund","family":"Folefac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Gregorevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dwight H.","family":"Owen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel K.","family":"Kulp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Latha P.","family":"Ganesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher C.","family":"Coss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Mace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitch A.","family":"Phelps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01056-8","article-title":"Next generation of immune checkpoint inhibitors and beyond","volume":"14","author":"Marin-Acevedo","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00149","article-title":"Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater","volume":"37","author":"Reck","year":"2019","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0415","article-title":"Pembrolizumab exposure-response assessments challenged by association of cancer cachexia and catabolic clearance","volume":"24","author":"Turner","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0910","article-title":"Effect of combined immune checkpoint inhibition vs best supportive care alone in patients with advanced colorectal cancer: the canadian cancer trials group CO.26 study","volume":"6","author":"Chen","year":"2020","journal-title":"JAMA Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andre","year":"2020","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1249980","article-title":"The prognostic biological markers of immunotherapy for non-small cell lung cancer: current landscape and future perspective","volume":"14","author":"Liang","year":"2023","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30607-1","article-title":"De-novo and acquired resistance to immune checkpoint targeting","volume":"18","author":"Syn","year":"2017","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-1683","article-title":"Antibody drug clearance: an underexplored marker of outcomes with checkpoint inhibitors","volume":"30","author":"Guo","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"17105","DOI":"10.1038\/nrdp.2017.105","article-title":"Cancer-associated cachexia","volume":"4","author":"Baracos","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.20452\/pamw.16135","article-title":"Sarcopenia and cachexia in chronic diseases: from mechanisms to treatment","volume":"131","author":"Lena","year":"2021","journal-title":"Pol Arch Intern Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.14734","article-title":"Cancer cachexia reduces the efficacy of nivolumab treatment in patients with advanced gastric cancer","volume":"40","author":"Fujii","year":"2020","journal-title":"Anticancer Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.12538","article-title":"Body composition is prognostic and predictive of ipilimumab activity in metastatic melanoma","volume":"11","author":"Chu","year":"2020","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"B13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.lungcan.2020.03.003","article-title":"Cachexia - sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors","volume":"143","author":"Roch","year":"2020","journal-title":"Lung Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2021.12.010","article-title":"Serum albumin: early prognostic marker of benefit for immune checkpoint inhibitor monotherapy but not chemoimmunotherapy","volume":"23","author":"Guo","year":"2022","journal-title":"Clin Lung Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s40257-018-0389-y","article-title":"Mechanisms of resistance to immune checkpoint blockade","volume":"20","author":"Liu","year":"2019","journal-title":"Am J Clin Dermatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/rco2.32","article-title":"Murine cancer cachexia models replicate elevated catabolic pembrolizumab clearance in humans","volume":"4","author":"Castillo","year":"2021","journal-title":"JCSM Rapid Commun"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.107048","article-title":"Decoupling FcRn and tumor contributions to elevated immune checkpoint inhibitor clearance in cancer cachexia","volume":"199","author":"Vu","year":"2023","journal-title":"Pharmacol Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e117","DOI":"10.1002\/rco2.117","article-title":"Intramuscular CMT-167 tumors produce a Mild Cachexia Phenotype in C57BL\/6J Mice","volume":"8","author":"Remaily","year":"2025","journal-title":"JCSM Commun"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2019.1602459","article-title":"Neonatal Fc receptor expression in macrophages is indispensable for IgG homeostasis","volume":"11","author":"Challa","year":"2019","journal-title":"MAbs"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal Fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.15366","article-title":"The neonatal Fc receptor: Key to homeostasic control of IgG and IgG-related biopharmaceuticals","volume":"19","author":"Baldwin","year":"2019","journal-title":"Am J Transplant"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00408","article-title":"The role of fcRn in antigen presentation","volume":"5","author":"Baker","year":"2014","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-014-0029-x","article-title":"The role of Fc gamma receptors in the activity of immunomodulatory antibodies for cancer","volume":"2","author":"Stewart","year":"2014","journal-title":"J Immunother Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000619","article-title":"FcgammaRII (CD32) modulates antibody clearance in NOD SCID mice leading to impaired antibody-mediated tumor cell deletion","volume":"8","author":"Oldham","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.08.004","article-title":"FcgammaRs modulate the anti-tumor activity of antibodies targeting the PD-1\/PD-L1 axis","volume":"28","author":"Dahan","year":"2015","journal-title":"Cancer Cell"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aal3604","article-title":"In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy","volume":"9","author":"Arlauckas","year":"2017","journal-title":"Sci Transl Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-018-2160-x","article-title":"The binding of an anti-PD-1 antibody to FcgammaRIota has a profound impact on its biological functions","volume":"67","author":"Zhang","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"B28","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4236\/abb.2013.44A004","article-title":"Fc receptors: Cell activators of antibody functions","volume":"4","author":"Rosales","year":"2013","journal-title":"Adv Biosci Biotechnol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-006-0052-1","article-title":"Activating and inhibitory FcgammaRs in autoimmune disorders","volume":"28","author":"Nimmerjahn","year":"2006","journal-title":"Springer Semin Immunopathol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003735","article-title":"Fc-null anti-PD-1 monoclonal antibodies deliver optimal checkpoint blockade in diverse immune environments","volume":"10","author":"Moreno-Vicente","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2017.1323159","article-title":"Affinity of human IgG subclasses to mouse Fc gamma receptors","volume":"9","author":"Dekkers","year":"2017","journal-title":"MAbs"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s11914-020-00628-w","article-title":"Sex differences in cancer cachexia","volume":"18","author":"Zhong","year":"2020","journal-title":"Curr Osteoporos Rep"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24054651","article-title":"Sex differences in inflammation and muscle wasting in aging and disease","volume":"24","author":"Della Peruta","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-3152","article-title":"Differential effects of IL6 and activin A in the development of cancer-associated cachexia","volume":"76","author":"Chen","year":"2016","journal-title":"Cancer Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.107048","article-title":"Decoupling FcRn and tumor contributions to elevated immune checkpoint inhibitor clearance in cancer cachexia","volume":"199","author":"Vu","year":"2024","journal-title":"Pharmacol Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2019.01324","article-title":"Mineralocorticoid receptor signaling contributes to normal muscle repair after acute injury","volume":"10","author":"Hauck","year":"2019","journal-title":"Front Physiol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23137066","article-title":"The neonatal fc receptor is elevated in monocyte-derived immune cells in pancreatic cancer","volume":"23","author":"Thomas","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B38","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1139\/H08-075","article-title":"A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care","volume":"33","author":"Mourtzakis","year":"2008","journal-title":"Appl Physiol Nutr Metab"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s13318-021-00722-z","article-title":"Population pharmacokinetic analysis from first-in-human data for HDAC inhibitor, REC-2282 (AR-42), in patients with solid tumors and hematologic Malignancies: A case study for evaluating flat vs. Body size normalized dosing","volume":"46","author":"Liva","year":"2021","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1017\/S0029665115004279","article-title":"Sarcopenia and cachexia in the era of obesity: clinical and nutritional impact","volume":"75","author":"Prado","year":"2016","journal-title":"Proc Nutr Soc"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1097\/SPC.0b013e328331124a","article-title":"The emerging role of computerized tomography in assessing cancer cachexia","volume":"3","author":"Prado","year":"2009","journal-title":"Curr Opin Support Palliat Care"},{"key":"B42","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1097\/FTD.0000000000000534","article-title":"Development of an enzyme-linked immune sorbent assay to measure nivolumab and pembrolizumab serum concentrations","volume":"40","author":"Basak","year":"2018","journal-title":"Ther Drug Monit"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12476","article-title":"Population pharmacokinetics of nivolumab in combination with ipilimumab in patients with advanced Malignancies","volume":"8","author":"Zhang","year":"2019","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-017-9528-y","article-title":"Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response","volume":"44","author":"Li","year":"2017","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00206.2021","article-title":"A semiautomated measurement of muscle fiber size using the Imaris software","volume":"321","author":"Gilda","year":"2021","journal-title":"Am J Physiol Cell Physiol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13395-018-0186-6","article-title":"Open-CSAM, a new tool for semi-automated analysis of myofiber cross-sectional area in regenerating adult skeletal muscle","volume":"9","author":"Desgeorges","year":"2019","journal-title":"Skelet Muscle"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-014-1545-8","article-title":"Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma","volume":"63","author":"Simeone","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.4110\/in.2020.20.e8","article-title":"Peripheral blood immune cell-based biomarkers in anti-PD-1\/PD-L1 therapy","volume":"20","author":"Kim","year":"2020","journal-title":"Immune Netw"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1177\/0148607108325075","article-title":"Myeloid-derived suppressor cells in cancer cachexia syndrome: a new explanation for an old problem","volume":"32","author":"Winfield","year":"2008","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1014515107","article-title":"FcgammaRIV deletion reveals its central role for IgG2a and IgG2b activity in vivo","volume":"107","author":"Nimmerjahn","year":"2010","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1126\/science.1118948","article-title":"Divergent immunoglobulin g subclass activity through selective Fc receptor binding","volume":"310","author":"Nimmerjahn","year":"2005","journal-title":"Science"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v99.3.754","article-title":"Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene","volume":"99","author":"Cartron","year":"2002","journal-title":"Blood"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.05.013","article-title":"Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma","volume":"21","author":"Weng","year":"2003","journal-title":"J Clin Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2008.182","article-title":"Altered balance of inhibitory and active Fc gamma receptors in murine autoimmune glomerulonephritis","volume":"74","author":"Ichii","year":"2008","journal-title":"Kidney Int"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2009.03138.x","article-title":"Disease activity in systemic lupus erythematosus is associated with an altered expression of low-affinity Fc gamma receptors and costimulatory molecules on dendritic cells","volume":"128","author":"Carreno","year":"2009","journal-title":"Immunology"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1669979\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T06:45:36Z","timestamp":1765953936000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1669979\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":55,"alternative-id":["10.3389\/fimmu.2025.1669979"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1669979","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]},"article-number":"1669979"}}